16 active not recruiting, 16 recruiting, 11 completed, 3 suspended. 31 Phase 1, 28 Phase 2, 5 Phase 3, 2 Early Phase 1.
Follow this drug Literature Review of iberdomide trials Research Report on iberdomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-16 |
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) Iberdomide, CAR-T Leukapheresis, CAR-T Infusion - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Shambavi Richard | 22 | 2026-07-01 | 2026-07-27 |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Etentamig, Iberdomide - Multiple Myeloma | Phase 1 | Recruiting | AbbVie | 135 | 2025-08-07 | 2026-05-12 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Isatuximab, Iberdomide, Dexamethasone - Smouldering Myeloma | Phase 2 | Recruiting | University College, London | 63 | 2025-06-02 | 2026-10-20 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan - Recurrent Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 37 | 2025-03-18 | 2026-06-25 |
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Iberdomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Canadian Myeloma Research Group | 75 | 2024-12-12 | 2026-08-31 |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 26 | 2024-12-06 | 2026-10-05 |
| Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Omar Nadeem, MD | 49 | 2024-11-01 | 2026-10-07 |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Suspended | National Cancer Institute (NCI) | 84 | 2024-08-27 | 2026-10-19 |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma Iberdomide, Isatuximab, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | University of Heidelberg Medical Center | 411 | 2024-04-05 | 2026-08-17 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 187 | 2024-02-22 | 2026-07-16 |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Iberdomide, Carfilzomib, Daratumumab - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 2 | Recruiting | Benjamin T Diamond, MD | 30 | 2024-02-20 | 2026-03-11 |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Elranatamab, Iberdomide - Multiple Myeloma | Phase 1 | Active not recruiting | Pfizer | 100 | 2024-02-20 | 2026-09-15 |
| Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Iberdomide, Daratumumab/rHuPH20 Co-formulation - Multiple Myeloma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 60 | 2023-12-21 | 2026-06-26 |
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma Cevostamab, Lenalidomide, Tocilizumab - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 200 | 2023-11-14 | 2026-10-06 |
Showing 20 of 54. Sign in to see all of them.
Multiple Myeloma (33) · Recurrence (4) · Lupus Erythematosus, Systemic (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Smoldering Multiple Myeloma (2) · Ganglioneuroblastoma (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Neuroblastoma (1) · Renal Insufficiency (1)
Celgene (15) · Bristol-Myers Squibb (3) · National Cancer Institute (NCI) (3) · AbbVie (2) · Celgene Corporation (2) · Dana-Farber Cancer Institute (2) · Hoffmann-La Roche (2) · Mayo Clinic (2) · PETHEMA Foundation (2) · Alfred Chung, MD (1) · Alliance for Clinical Trials in Oncology (1) · Amsterdam UMC, location VUmc (1) · Barbara Ann Karmanos Cancer Institute (1) · Benjamin T Diamond, MD (1) · Canadian Myeloma Research Group (1)
United States (43) · Spain (12) · France (11) · Australia (8) · Canada (8) · Germany (7) · Italy (7) · United Kingdom (7) · Netherlands (6) · South Korea (6) · Belgium (5) · Israel (5) · Japan (5) · Poland (5) · Taiwan (5)
Maria Palmisano, MD (3) · Daniel Weiss, MD (2) · Alfred Chung, MD (1) · Alice Wang, MD (1) · Benjamin Diamond, MD (1) · Carl O Landgren, MD, PhD (1) · Cesar Rodriguez, MD (1) · Cliford Mo, MD (1) · Clifton C. Mo, MD (1) · Cyrille Touzeau (1) · Debra Mandarino, MD (1) · Enrique M Ocio, Dr (1)
PMID 33687069, PMID 32965548, PMID 32989091, PMID 33626253, PMID 34515338, PMID 35177672, PMID 35294813, PMID 35477518, PMID 36209764, PMID 36762851, PMID 37272512, PMID 38230766, PMID 38521893, PMID 38703748, PMID 38776914, PMID 39870177, PMID 40346992, PMID 41482445, PMID 42158929, PMID 42790445
2023 (2), 2014 (1), 2016 (1), 2019 (1), P30CA138292 (1), U10CA180821 (1), U10CA180886 (1), UM1CA186709 (1)